Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.
about
Quetiapine versus other atypical antipsychotics for schizophreniaAntipsychotic drug treatment for elderly people with late-onset schizophreniaZiprasidone versus other atypical antipsychotics for schizophreniaImpact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophreniaMedication adherence in schizophreniaAn in vitro analysis of disintegration times of different formulations of olanzapine orodispersible tablet: a preliminary report.The metabolic basis of cognitive insight in psychosis: A positron emission tomography studyTreatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medicationInsight as a social identity process in the evolution of psychosocial functioning in the early phase of psychosis.Attitudes towards antipsychotics among patients with schizophrenia on first- or second-generation medications.Assessing cognitive insight in nonpsychiatric individuals and outpatients with schizophrenia in Taiwan: an investigation using the Beck Cognitive Insight Scale.Patient perspectives on antipsychotic treatments and their association with clinical outcomes.Patients' preference for olanzapine orodispersible tablet compared with conventional oral tablet in a multinational, randomized, crossover study.Insight, psychopathology, explanatory models and outcome of schizophrenia in India: a prospective 5-year cohort studyPaliperidone extended-release: does it have a place in antipsychotic therapy?Illness denial in schizophrenia spectrum disorders: a function of left hemisphere dominancePsychometric properties of the abbreviated version of the Scale to Assess Unawareness in Mental Disorder in schizophrenia.The effects of aging on insight into illness in schizophrenia: a review.Relationship between cognitive insight and subjective quality of life in outpatients with schizophrenia.Prevalence and predictors of sub-optimal medication adherence among patients with severe mental illnesses in a tertiary psychiatric facility in Maiduguri, North-eastern Nigeria.Satisfaction of immediate or delayed switch to paliperidone palmitate in patients unsatisfied with current oral atypical antipsychoticsQualitative process evaluation of a psycho-educational intervention targeted at people diagnosed with schizophrenia and their primary caregivers in Jordan.Insight and subjective measures of quality of life in chronic schizophrenia.The Role of Insight in Moderating the Association Between Depressive Symptoms in People With Schizophrenia and Stigma Among Their Nearest Relatives: A Pilot Study.Safety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia.Insight in Psychosis: An Indicator of Severity of Psychosis, an Explanatory Model of Illness, and a Coping Strategy.Reasoning and Rehabilitation cognitive skills programme for mentally disordered offenders: Predictors of outcome.Lack of awareness of illness in schizophrenia: conceptualizations, correlates and treatment approaches.Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness.Insight in bipolar disorder.Insight in schizophrenia: from conceptualization to neuroscience.Directions for future patient-centered and comparative effectiveness research for people with serious mental illness in a learning mental health care systemConsciousness, awareness of insight and neural mechanisms of schizophrenia.The influence of therapeutic alliance and insight on medication adherence in schizophrenia.Long-term effects of involuntary hospitalization on medication adherence, treatment engagement and perception of coercion.Medication adherence in patients with psychotic disorders: an observational survey involving patients before they switch to long-acting injectable risperidone.Treatment adherence in schizophrenia: a patient-level meta-analysis of combined CATIE and EUFEST studies.Short-term clinical stability and lack of insight are associated with a negative attitude towards antipsychotic treatment at discharge in patients with schizophrenia and bipolar disorder.Understanding and measuring recovery.Predictors of medication non-adherence in Bulgarian outpatients with schizophrenia.
P2860
Q24202427-7B44B3EB-A530-4F76-B1A8-94AD04EA69C4Q24203649-11B9D108-5D8C-46D3-8B03-C4FB76C69078Q24240260-4E242602-94BB-4943-931B-82E8D11E18E1Q24597701-23FA7156-3A19-4387-B8C7-B92CD9409ACEQ26823655-C8B10751-FDB5-4EED-A016-4D7A346BE09BQ30561799-C555B786-8512-4BF3-A8B8-32316D517BDCQ33570874-62A4C428-54CC-4FEC-8D16-E15A9B29EAB2Q33595935-59E2C3CB-3E59-4E67-9F66-13B973003E46Q33661919-B39F8260-17DD-48F7-848F-8C33C084DEBFQ33908823-E5793328-A28B-4AC9-AF3E-FE4AD503327AQ34054162-07BDD957-3547-4642-8E66-0246FFBEB295Q34231565-F99C61EC-A9A1-496F-947E-700BAF47FC74Q34308680-4341C034-E37F-4BD8-82BF-2E578EDC6A0FQ34421748-8222901D-EE5F-4BCE-8E9D-581D1304DF04Q34712339-07B87FF3-13F9-4B6D-BA25-8BAAD13E3ED1Q34715809-6802D7A9-22C3-4D39-AA88-015DEBA0D587Q34993118-6D2B6550-0F6B-487C-8C0C-F178DAE89B36Q35756601-B6A20C5A-7B4A-4E97-B30C-C693E9FF78ADQ35950526-9AD213E2-AC46-46A5-9F1B-27D14B921E2CQ36042870-0CD299D0-E272-46AA-A5C8-67D578A9B2F0Q36121675-27095F86-8B3D-4850-AF90-CE39899A40C8Q36279110-C3C70CE3-3B39-43B0-9769-D63A8092EB56Q36677817-04C570FE-2935-49FB-A41F-D9537526F692Q36817300-9C32E22D-7616-43B1-B4B3-0A27E3AD2001Q36873906-00B621C0-8759-49F6-9FE8-F56C6D93D8A2Q36997219-64301480-3E52-4E68-B8C1-BC60815C36CEQ37532004-3235B89D-E918-49A6-8E4F-F8DA1E441636Q37546087-59482B41-666E-4F3B-8E22-D49A94C7907EQ37691609-63C148E1-9639-4416-989A-A09FA4F2CD47Q37958715-8A45AC94-98C3-4502-B6DF-561AB8BADBD7Q37996450-8481FFB8-8F38-45C4-9828-6730BBE4D1E5Q38184528-2C54516E-FE24-4304-8EE2-77EFD219B6ADQ38367891-611470D6-C749-4222-BED3-F8BF223C523EQ38462579-1B569AFE-FAA6-4761-BA27-9B24EB663F97Q39432205-77BABF2C-62E7-47B5-BB87-4F2EF138B837Q40512185-4F5EA368-C9B1-4B4B-8A47-DE248D6A4663Q40906666-8679F737-5F37-4106-B47B-56854CA215C2Q41788185-C56B8CA4-50A2-4B92-94E0-26B3CB8E0B71Q43158450-7852B91D-B67C-4410-BDFE-02DBF743CA62Q43926986-A30FE4B9-B953-4111-8E6F-4A47447D6782
P2860
Cross-sectional and longitudinal relationships between insight and attitudes toward medication and clinical outcomes in chronic schizophrenia.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 26 June 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Cross-sectional and longitudin ...... omes in chronic schizophrenia.
@en
Cross-sectional and longitudin ...... omes in chronic schizophrenia.
@nl
type
label
Cross-sectional and longitudin ...... omes in chronic schizophrenia.
@en
Cross-sectional and longitudin ...... omes in chronic schizophrenia.
@nl
prefLabel
Cross-sectional and longitudin ...... omes in chronic schizophrenia.
@en
Cross-sectional and longitudin ...... omes in chronic schizophrenia.
@nl
P2093
P2860
P356
P1476
Cross-sectional and longitudin ...... omes in chronic schizophrenia.
@en
P2093
Jeffrey A Lieberman
Joseph McEvoy
Marvin Swartz
Scott Stroup
Somaia Mohamed
P2860
P304
P356
10.1093/SCHBUL/SBN067
P407
P577
2008-06-26T00:00:00Z